Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Oral medicament for treating cerebral infarction and relieving limb spasm

A technology for cerebral infarction and limbs, applied in the field of plant materials, can solve the problems of non-concentrated curative effect, unprominent curative effect, and weak pertinence, etc., and achieve the effects of reducing infarct size, improving hemorheology indicators, and prolonging gasping time

Inactive Publication Date: 2012-05-23
马耀茹
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] The currently marketed medicines for the treatment of cerebral infarction can be divided into two categories. One is local standard old medicines listed in the early stage, such as Huatuo Zaizao Pills, Zhongfeng Huichun Pills, etc. These products have not undergone strict randomized and double-blind trials. , controlled, and multi-center clinical trials, the curative effect needs to be further confirmed, and the indications are wide, and the curative effect is not concentrated; one is Chinese patent medicines approved in recent years, such as Nao'an Capsules, Naoxintong Capsules, etc. , but they are all large and comprehensive products, the curative effect is not outstanding, and the pertinence is not strong

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Oral medicament for treating cerebral infarction and relieving limb spasm
  • Oral medicament for treating cerebral infarction and relieving limb spasm
  • Oral medicament for treating cerebral infarction and relieving limb spasm

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0040] Taking the production of 1000 pharmaceutical capsule products of the present invention as an example, the used Chinese medicine raw materials and auxiliary materials and their proportioning ratio are:

[0041] Astragalus 270g

[0042] Pueraria 270g

[0043] Radix Paeoniae Alba 210g

[0044] Chuanxiong 180g

[0045] 150g peach kernels

[0046] Milletweed 180g

[0047] Tendon Grass 180g

[0048] Wexgrass 180g

[0049] Achyranthes knuckle 120g

[0050] Dilong 60g

[0051] Add dextrin to 400g

[0052] Its preparation method is as follows:

[0053] Take astragalus and other ten kinds of herbs, 90g of kudzu herbs, powder, pass through a 100-mesh sieve, and set aside; the remaining kudzu herbs and other nine herbs are decocted twice, adding 10 times the amount of water for 2 hours for the first time. Add 8 times the amount of water twice and decoct for 2 hours, filter, combine the filtrates, concentrate to a relative density of 1.20±0.05 (measured at 60°C), add ethan...

Embodiment 2

[0089] Taking the production of 1000 pharmaceutical capsule products of the present invention as an example, the used Chinese medicine raw materials and auxiliary materials and their proportioning ratio are:

[0090] Astragalus 231g

[0091] Pueraria 231g

[0092] Radix Paeoniae Rubra 194g

[0093] Chuanxiong 194g

[0094] 194g peach kernels

[0095] Milletweed 194g

[0096] Tendon Grass 194g

[0097] Wexgrass 194g

[0098] Achyranthes knuckle 116g

[0099] Dilong 58g

[0100] Add dextrin to 400g

[0101] Its preparation process is identical with the preparation process of embodiment 1 capsule. Each grain weighs 0.4g, and each gram contains 4.5g of traditional Chinese medicine raw materials.

[0102] Taking the production of 1000 tablets of the pharmaceutical tablet product of the present invention as an example, the used Chinese medicine raw materials and auxiliary materials and their proportioning ratio are as follows:

[0103] The raw materials used in the tablet...

Embodiment 3

[0137] Taking the production of 1000 pharmaceutical capsule products of the present invention as an example, the used Chinese medicine raw materials and auxiliary materials and their proportioning ratio are:

[0138] Astragalus 282g

[0139] Pueraria 282g

[0140] Radix Paeoniae Alba 176g

[0141] Chuanxiong 176g

[0142] 141g peach kernels

[0143] Spatholobus 177g

[0144] Tendon Grass 177g

[0145] Wexgrass 177g

[0146] Achyranthes knuckle 141g

[0147] Dilong 71g

[0148] Add dextrin to 400g

[0149] Its preparation process is identical with the preparation process of embodiment 1 capsule. Each grain weighs 0.4g, and each gram contains 4.5g of traditional Chinese medicine raw materials.

[0150] Taking the production of 1000 tablets of the pharmaceutical tablet product of the present invention as an example, the used Chinese medicine raw materials and auxiliary materials and their proportioning ratio are:

[0151] The raw materials used in the tablet of this em...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an oral medicament for treating cerebral infarction and relieving limb spasm, and the oral medicament is prepared from the following traditional Chinese medicine active ingredients in parts by weight: 12-40 parts of membranous milkvetch root, 12-40 parts of pachyrhizua angulatus, 10-25 parts of red paeony root, 10-25 parts of szechuan lovage rhizome, 10-20 parts of peach seed, 10-25 parts of suberect spatholobus stem, 10-25 parts of common clubmoss herb, 10-25 parts of glandularstalk st.paulswort herb, 6-20 parts of twotooth achyranthes root and 3-10 parts of earthworm. Efficacy tests prove that the medicament can obviously inhibit the in-vivo blood vessel thrombosis of an animal, reduce the weight of in-vivo arterial and venous thrombus, inhibit the thrombosis and alleviate the clinical symptoms caused by the thrombus; and the medicament further has certain effect of improving coagulation function of rats, and can reduce the platelet aggregation rate, prolongthe coagulation time, the PT (prothrombin time) and the APTT (activated partial thromboplastin time), have an obvious effect of improving blood rheology indicators, and can be used for significantly reducing blood viscosity of a rat blood stasis model caused by polymer dextran, improving the blood circulation, and avoiding the potential risk of the thrombosis.

Description

technical field [0001] The invention belongs to the technical field of medical preparations containing raw materials or their reaction products with unknown structures, and specifically relates to materials derived from plants. Background technique [0002] Stroke, also known as stroke and cerebrovascular accident, usually refers to a group of acute diseases including cerebral hemorrhage, cerebral infarction and subarachnoid hemorrhage. Cerebrovascular clinical events with signs of functional loss are common and frequently-occurring diseases of middle-aged and elderly people. They are one of the three diseases with the highest human mortality rate. The most disabling disease causes great suffering to human beings and serious harm to families and society. Moreover, as people's dietary structure changes and the pace of life accelerates, the incidence of stroke increases year by year and tends to become younger. 4.6 million people die from stroke every year in the world, and ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K36/736A61K36/71A61K36/488A61K36/486A61K36/481A61K36/28A61K36/236A61K36/21A61K36/11A61K35/64A61P9/10A61P21/00A61K35/62
Inventor 马耀茹
Owner 马耀茹
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products